Published in final edited form as:

Ann Neurol. 2018 November ; 84(5): 788–795. doi:10.1002/ana.25350.

NBEA: developmental disease gene with early generalized epilepsy phenotypes

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

NBEA is a candidate gene for autism, and *de novo* variants have been reported in neurodevelopmental disease (NDD) cohorts. However, *NBEA* has not been rigorously evaluated as a disease gene, and associated phenotypes have not been delineated. We identified 24 *de novo* *NBEA* variants in patients with NDD, establishing *NBEA* as an NDD gene. Most patients had epilepsy with onset in the first few years of life, often characterized by generalized seizure types, including myoclonic and atonic seizures. Our data show a broader phenotypic spectrum than previously described, including a Myoclonic-Astatic Epilepsy (MAE)-like phenotype in a subset of patients.

Introduction:

NBEA encodes Neurobeachin, a brain-specific kinase-anchoring protein implicated in vesicle trafficking and synaptic structure and function¹. It is not currently associated with disease in the Online Mendelian Inheritance in Man (OMIM) database but is a candidate gene for autism based on linkage studies and the identification of microdeletions and a reciprocal balanced translocation involving *NBEA* in patients with autism^{2–6}. More recently, two *de novo* *NBEA* variants were identified through whole exome sequencing (WES) in large cohorts of patients with neurodevelopmental disease (NDD) phenotypes, implicating *NBEA* as a candidate gene⁷.

Here we report 24 *de novo* *NBEA* variants, including 18 identified through clinical and research sequencing and six *de novo* deletions identified by array or whole genome sequencing (WGS). *De novo* *NBEA* mutations were associated with NDD in all patients and epilepsy in the majority. Of those with epilepsy, most had generalized seizure types and seizure onset in the first few years of life. A subset had features of Myoclonic-Astatic Epilepsy (MAE), with toddler age onset of myoclonic, atonic and/or myoclonic-atonic

Corresponding author: Tristan T. Sands, MD, PhD, Tts27@cumc.columbia.edu, 180 Fort Washington Avenue, Harkness Pavilion 5th Floor, New York, NY 10032, Phone: (212) 342-6867, Fax: (212) 342-6865.

Author Contributions

Acquisition and analysis of data: MSM, CS, NS, HGB, LB, NL, JR, RPWR, MK, RP, APAS, MKK, AT, AH, ELR, NH, MB, NH, MJVH, SW, JR, TD, DB, BC, DC, JRL, CK, HCM, CTM, ZS, SMH, GMC, EMB, LSB, HEVK, EHB, EHB, CVT, EB, ARP, EP, DM, MP, BI, CLC, BGD, FB, ELH, DBG, SJCS, TTS. Study concept and design: TTS, ELH, DBG, and SJCS. Drafting the text and preparing the figures: MSM, TTS, ELH, and NS.

Potential Conflicts of Interest

There are no potential conflicts of interest relevant to this manuscript.

seizures and, in some cases, developmental regression with seizure onset. Epilepsy has not been described in previous reports implicating *NBEA* as an autism candidate gene, but our data support that it is a major feature in patients with variants in *NBEA*.

Methods:

NBEA variants were identified by research trio WES for individuals 1, 6, 10, 14 and 18 and research trio WGS for individual 13 and 24. Individuals 11 and 12 and their parents underwent sequencing of a panel of candidate genes based off of a previous sequencing project. Variants identified in individuals 1, 10, 12, 13, 14 and 18 were confirmed by Sanger sequencing. For individual 24, the deletion was confirmed by research GSA array. For individual 19, the deletion was identified through a research protocol using SNP array. *NBEA* variants were identified in individuals 2–5, 7–9, 15–17 through clinical WES, and were either Sanger confirmed or met laboratory criteria for reporting based on WES only. Individuals 20–23 and their parents underwent clinical microarray. Informed consent was obtained by parents and all research studies received prior approval by the appropriate Institutional Review Board. Groups were connected through GeneMatcher ⁸.

Results:

NBEA variants were identified in 22 previously unreported cases and two cases already reported in the literature ⁷. All variants were confirmed to be *de novo* with the exception of individual 13. For individual 13, parents were unavailable for Sanger confirmation, but we presumed (based on demographic information and referral site) that this was the same person included in an epileptic encephalopathy cohort, where the variant was confirmed to be *de novo* ^{9, 10}. Variant types identified included nonsense (8/24), frameshift (5/24), missense (4/24), intragenic deletion (5/24), splice site (1/24), and a multi-gene deletion (1/24). All variants were absent from gnomAD and from 12,325 internal Institute for Genomic Medicine (IGM) controls ¹¹. Each of the missense variants were predicted to be deleterious by at least one computational model; of the four missense variants, three were predicted probably damaging and one possibly damaging (ind. 17) by PolyPhen2 and all had an adjusted CADD score greater than 20. Two were found within WD-40 repeats ¹² (Figure 1). *NBEA* encodes two CCDS transcripts—the 2946 amino acid CCDS45026/NM_015678 (NP_056493.3) and a shorter 739 amino acid CCDS55894/NM_001204197 (NP_001191126.1). All variants identified in our cohort affected the longer transcript, and eight affected both. Nonsense and frameshift variants from our cohort occurred throughout the protein (NP_056493.3). All deletions were intragenic, except for the 2.87 Mb deletion identified in individual 19, which contains multiple other genes, none of which are known to be associated with disease based on OMIM.

All patients had NDD, including developmental delay (DD) and/or intellectual disability (ID) (Table 1). Age of ambulation ranged from 11 months to 3.5 years; one person (individual 11) is non-ambulatory as an adult. All patients had some level of speech delay, and two patients are non-verbal at 11 and 19 years (Table 2). Two patients had developmental regression noted at the time of seizure onset. Half of the patients (12/24) had autism or prominent autistic features.

The majority of patients (15/24) had epilepsy, and two additional patients have presumed or possible epilepsy. Of those with classified epilepsy, one had focal epilepsy; the rest have generalized epilepsy or mixed (focal and generalized) epilepsy with multiple seizure types. Myoclonic seizures were common, present in almost half of those with epilepsy (7/15). Of these, four presented with a MAE-like phenotype, with toddler onset atonic and/or myoclonic-atic seizures. Myoclonic seizures were more common in patients with LoF variants (6/12, 50%) than those with missense variants (1/3, 33.3%), and all cases of atonic and/or myoclonic-atic seizures (n=5) were found in individuals with a LoF mutation.

About three-quarters of patients with epilepsy had seizure onset between 1–4 years of age. The two individuals with seizure onset at less than 1 year of age both had LoF variants. Response to treatment was variable, some patients had cessation of seizures between the ages of 3 and 19 years old, while others remain refractory to treatment. Some success was reported using valproic acid, ethosuximide (with valproic acid), levetiracetam, lamotrigine, benzodiazepines and dietary therapy, usually in some combination (Table 2). The interictal EEG often showed diffuse slowing and included generalized epileptiform abnormalities in the majority of patients with epilepsy (9/15, 60%). MRIs did not show any distinctive features in most patients.

Seven participants had behavior problems including aggression (4/24) and attention deficits and hyperactivity (4/24). Eight patients had abnormal movements, including wide-based, uncoordinated gait (6/24) and dystonic movements (3/24); one additional patient was noted to be “clumsy”. Other features reported in more than one patient include hypotonia of variable severity (8/24), microcephaly or borderline microcephaly (3/24), recurrent infections (2/24) and eczema or dry skin (3/24). All of those with microcephaly had LoF variants.

Discussion:

We have demonstrated that *NBEA* is an NDD gene, associated with early childhood epilepsy, which is consistent with what is known about the biology of *NBEA*. Neurobeachin (*NBEA*) is a brain-specific multidomain scaffolding protein belonging to the family of BEACH (Beige and Chediak-Higashi) domain-containing proteins, which play a role in vesicle trafficking and dynamics^{1, 13}. *NBEA* localizes to vesicular structures at the trans-face of the Golgi and within neuronal dendrites and appears to regulate synaptic structure and function through targeted trafficking of post-synaptic proteins^{14, 15}. In zebrafish, post-synaptic *NBEA* is essential for both electrical and chemical synapse formation and maintenance of dendritic complexity¹⁶. Our work adds to a growing body of literature implicating genes encoding synaptic proteins in neurodevelopmental disorders associated with epilepsy, autism and intellectual disability, although the specific mechanism by which these variants give rise to NDD is unknown.^{17, 18}

NBEA has been considered an autism candidate gene, and *de novo NBEA* variants have been seen in NDD cohorts. A large genetic linkage study indicated the 19 cM segment on chromosome 13 containing *NBEA* as a candidate region for autism². A patient with sporadic autism was found to have a *de novo* balanced reciprocal translocation (t(5;13)

(q12.1;q13.2)) disrupting *NBEA*³. Three patients with autism have been described in the literature with monoallelic deletions that include *NBEA*^{4–6}. Two individuals with *de novo* *NBEA* single nucleotide variants (individuals 13 and 14) were previously described in a cohort with ID and/or DD⁷. While *NBEA* has been prioritized as a strong candidate epileptic encephalopathy (EE) gene based on high level of co-expression with known EE genes in the adult and developing brain, an association with epilepsy has not previously been reported¹⁹.

In reporting 24 patients with NDD harboring *de novo* variants absent from population databases, we provide substantial genetic evidence implicating *NBEA* in disease. The majority of the variants (20/24) predict loss of function and *NBEA* is extremely intolerant to loss-of-function variation (pLI=1, RVIS (ExAC v2)=1.16%)^{11, 20}, suggesting a haploinsufficiency disease mechanism. Our work complements experimental data demonstrating a role for *NBEA* at the synapse and autism-like behaviors modeled in the *Nbea*^{+/-} mouse²¹. Applying ClinGen's clinical validity of gene-disease associations framework, we therefore conclude that there is "strong" evidence that pathogenic variants in *NBEA* cause NDD with and without epilepsy²².

In terms of the overall phenotype of the cohort, language delay was universal, but the vast majority of patients were ultimately verbal, and almost all patients were ambulatory by 4 years of age; half had autism or autistic features and half had epilepsy within the first years of life, typically a generalized epilepsy often with myoclonic seizures. A subset had an MAE-like phenotype.

MAE is rare, accounting for only 1–2% of epilepsy in the first decade of life²³. While a genetic etiology was speculated in the first description by Doose, the vast majority of cases of MAE remain genetically unexplained. MAE-like phenotypes have been described in association with variants in *SLC2A1*, *SCN1A*, *SCN1B*, *GABRG2* and *GABRB3*^{24–26}. The core *NBEA* associated epilepsy in our cohort involves toddler-age onset of multiple generalized seizure types, especially myoclonic seizures, with MAE-like phenotypes similar to what has been described for *CHD2* and *SLC6A1*. As with these genes, the phenotypic spectrum of *NBEA* epilepsy includes patients with features atypical for MAE, such as developmental delay preceding seizure onset and the presence of focal epileptiform discharges and/or focal seizures in some patients^{27–29}. A limitation of the current study is the lack of standardization in the evaluation of patients. Diagnosis of seizure types and syndromes and EEG interpretation were as determined by the treating neurologists. Future work with centralized review of polygraphic video-EEG for each reported seizure type and a common neuropsychological battery applied universally across the cohort will give a better understanding of the *NBEA* phenotypic spectrum.

While the small number of, and lack of recurrent, missense variants limit our ability to make definite phenotype-genotype correlations, it is perhaps notable that MAE seizure types, including myoclonic, atonic and/or myoclonic-atonic seizures, were seen almost exclusively with LoF variants. Additionally, epilepsy with onset in infancy and microcephaly or borderline microcephaly were each only seen with LoF variants, possibly reflecting a more severe phenotypic spectrum in this group.

In addition to the cases from our cohort, three other *de novo* missense variants are reported in denovo-db (<http://denovo-db.gs.washington.edu>) from various NDD cohorts, although *NBEA* variants were not significant in any of these cohorts. The cohorts included autism spectrum disorders, schizophrenia, and developmental disability/intellectual disability, but none of these individuals were specifically reported to have epilepsy or seizures^{30–32}. Individual 4 was previously included in an ID cohort, and as mentioned before, individual 13 was probably previously included in an epileptic encephalopathy cohort^{9, 10, 33}. Notably, the same nonsense variant seen in individual 2 was identified in a (possibly) unique person in an autism spectrum disorder cohort; individual 2 also had a diagnosis of autism³⁴. One *de novo* missense variant was identified in a control individual; this was not located in a known functional domain and is predicted benign by PolyPhen-2 (Figure 1).³⁴

In conclusion, by gathering genetic data from multiple sites connected through GeneMatcher, we identified 24 *de novo* variants in *NBEA* identified through either research or clinical genetic testing. This study implicates *NBEA* as a neurodevelopmental gene with distinctive epilepsy presentations in the first years of life, overlapping MAE phenotypes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Maureen S. Mulhern, MS^{#1}, Constance Stumpel, MD, PhD^{#2}, Nicholas Stong, PhD¹, Han G. Brunner, MD^{2,3}, Louise Bier, MS¹, Natalie Lippa, MS¹, James Riviello, MD⁴, Rob P.W. Rouhl, MD, PhD^{5,6,7}, Marlies Kempers, MD⁸, Rolph Pfundt, PhD³, Alexander P.A. Stegmann, PhD², Mary K. Kukulich, MD⁹, Aida Telegrafi, MS¹⁰, Anna Lehman, MD¹¹ **on behalf of CAUSES study**, Elena Lopez-Rangel, MD¹¹, Nada Houcinat, MD^{12,13}, Magalie Barth, MD¹⁴, Nicolette den Hollander, MD, PhD¹⁵, Mariette JV Hoffer, PhD¹⁵, Sarah Weckhuysen, MD, PhD^{16,18} **on behalf of EuroEPINOMICS-RES-MAE working group**, Jolien Roovers, MS^{16,17}, Tania Djemie, PhD^{16,18}, Diana Barca, MD, PhD¹⁹, Berten Ceulemans, MD, PhD²⁰, Dana Craiu, MD, PhD¹⁹, Johannes R. Lemke, MD²¹, Christian Korff, MD²², Heather C. Mefford, MD, PhD²³, Candace T. Meyers, PhD²³, Zsuzsanna Siegler, MD²⁴, Susan M. Hiatt, PhD²⁵, Gregory M. Cooper, PhD²⁵, E. Martina Bebin, MD²⁶, Lot Snijders-Blok, MD^{3,27}, Hermine E. Veenstra-Knol, MD²⁸, Evan H. Baugh, PhD¹, E.H. Brilstra, MD²⁹, Catharina M.L. Volker-Touw, MD, PhD²⁹, Ellen van Binsbergen, MsC²⁹, Anya Revah-Politi, MS¹, Elaine Pereira, MD³⁰, Danielle McBrien, MD⁴, Mathilde Pacault, MD³¹, Bertrand Isidor, MD, PhD³¹, Cedric Le Caignec, MD, PhD³¹, Brigitte Gilbert-Dussardier, MD^{32,33}, Frederic Bilan, PhD^{32,33}, Erin L. Heinzen, PharmD, PhD^{1,34}, David B. Goldstein, PhD¹, Servi J. C. Stevens, PhD^{#2}, and Tristan T. Sands, MD, PhD^{#1}

Affiliations

¹Columbia University Medical Center, Institute for Genomic Medicine, New York, NY, USA ²Department of Clinical Genetics and School for Oncology and

Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, NL ³Radboud University Medical Center, Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, NL ⁴Columbia University Medical Center, Department of Neurology, New York, NY, USA ⁵Maastricht University Medical Center (MUMC+), Department of Neurology, Maastricht, NL ⁶Academic Center for Epileptology, Kempenhaeghe/MUMC+, Maastricht, NL ⁷Maastricht University, School for Mental Health and Neuroscience, Maastricht, NL ⁸Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, NL ⁹Cook Children's Hospital, Fort Worth, TX, USA ¹⁰GeneDx, Gaithersburg, MD, USA ¹¹University of British Columbia, Medical Genetics, Vancouver, BC, CAN ¹²Université Bourgogne-Franche Comté, UMR1231 GAD, Inserm, Dijon, FR ¹³CHU Dijon Bourgogne, Centre de Référence maladies rares « Anomalies du développement et syndromes malformatifs », centre de génétique, FHU-TRANSLAD, Dijon, FR ¹⁴CHU d'Angers, Département de Biochimie et Génétique, Angers, FR ¹⁵Leiden University Medical Center, Clinical Genetics, Leiden, NL ¹⁶Center for Molecular Neurology, VIB, Neurogenetics Group, Antwerp, BE ¹⁷University of Antwerp, Laboratory of Neurogenetics, Institute Born-Bunge, Antwerp, BE ¹⁸University Hospital Antwerp, Department of Neurology, Antwerp, BE ¹⁹“Carol Davila” University of Medicine, Pediatric Neurology Clinic, Al Obregia Hospital, Bucharest, RO ²⁰University Hospital Antwerp, Department of Pediatric Neurology, Antwerp, BE ²¹University of Leipzig Hospitals and Clinics, Institute for Human Genetics, Leipzig, DE ²²Pediatric Neurology Unit, Child and Adolescent Department, University Hospitals, Geneva, Switzerland ²³University of Washington, Department of Pediatrics, Seattle, WA, USA ²⁴Bethesda Children's Hospital, Department of Neurology, Budapest, HU ²⁵HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA ²⁶University of Alabama at Birmingham, Department of Neurology, Birmingham, AL, USA ²⁷Language & Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, NL ²⁸University of Groningen, Department of Genetics, University Medical Centre Groningen, Groningen, NL ²⁹University Medical Center Utrecht, Department of Medical Genetics, Utrecht, NL ³⁰Columbia University Medical Center, New York-Presbyterian Morgan Stanley Children's Hospital, Department of Pediatrics, Division of Clinical Genetics, New York, NY, USA ³¹CHU Nantes, Service de Génétique, Nantes, FR ³²CHU de Poitiers, Service de Génétique, FR ³³Université de Poitiers, EA3808 NEUVACOD, FR ³⁴Columbia University Medical Center, Department of Pathology and Cell Biology, New York, NY, USA

Acknowledgements

We are very appreciative of all the families who enrolled in the various research studies involved. Individual 6 was enrolled through the CAUSES study, which is funded by British Columbia Children's Hospital Foundation (Mining for Miracles) and Genome BC. Investigators in the CAUSES study include Shelin Adam, Christele Du Souich, Alison Elliott, Anna Lehman, Jill Mwenifumbo, Tanya Nelson, Clara Van Karnebeek, and Jan Friedman. We also thank individuals and groups who contributed exome sequence samples for analysis, including the Epi4K Consortium, the Epilepsy Phenome Genome Project (EPGP), EuroEPINOMICS-RES Consortium, and Dr. Vandana Shashi and Dr. Ann Bergin. This publication was supported by the National Center for Advancing Translational

Sciences, National Institutes of Health, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Wang X, Herberg FW, Laue MM, et al. Neurobeachin: A protein kinase A-anchoring, beige/Chediak-higashi protein homolog implicated in neuronal membrane traffic. *J Neurosci* 2000;20:8551–8565.
2. Barrett S, Beck JC, Bernier R, et al. An autosomal genomic screen for autism. Collaborative linkage study of autism. *Am J Med Genet* 1999;88:609–615. [PubMed: 10581478]
3. Castermans D, Wilquet V, Parthoens E, et al. The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism. *J Med Genet* 2003;40:352–356. [PubMed: 12746398]
4. Smith M, Woodroffe A, Smith R, et al. Molecular genetic delineation of a deletion of chromosome 13q12-->q13 in a patient with autism and auditory processing deficits. *Cytogenet Genome Res* 2002;98:233–239. [PubMed: 12826745]
5. Steele MM, Al-Adeimi M, Siu VM, Fan YS. Brief report: A case of autism with interstitial deletion of chromosome 13. *J Autism Dev Disord* 2001;31:231–234. [PubMed: 11450821]
6. Ritvo ER, Mason-Brothers A, Menkes JH, Sparkes RS. Association of autism, retinoblastoma, and reduced esterase D activity. *Arch Gen Psychiatry* 1988;45:600. [PubMed: 3377648]
7. Bowling KM, Thompson ML, Amaral MD, et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. *Genome Med* 2017;9:43. [PubMed: 28554332]
8. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* 2015;36:928–930. [PubMed: 26220891]
9. Epi4K Consortium. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217–221. [PubMed: 23934111]
10. Euro E-RESC, Epilepsy Phenome/Genome Project, Epi4K Consortium. De novo mutations in synaptic transmission genes including DNMT1 cause epileptic encephalopathies. *Am J Hum Genet* 2014;95:360–370. [PubMed: 25262651]
11. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–291. [PubMed: 27535533]
12. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310–315. [PubMed: 24487276]
13. Cullinane AR, Schaffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. *Traffic* 2013;14:749–766. [PubMed: 23521701]
14. Nair R, Lauks J, Jung S, et al. Neurobeachin regulates neurotransmitter receptor trafficking to synapses. *J Cell Biol* 2013;200:61–80. [PubMed: 23277425]
15. Niesmann K, Breuer D, Brockhaus J, et al. Dendritic spine formation and synaptic function require neurobeachin. *Nat Commun* 2011;2:557. [PubMed: 22109531]
16. Miller AC, Voelker LH, Shah AN, Moens CB. Neurobeachin is required postsynaptically for electrical and chemical synapse formation. *Curr Biol* 2015;25:16–28. [PubMed: 25484298]
17. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. *Cold Spring Harb Perspect Biol* 2012;4.
18. Fukata Y, Fukata M. Epilepsy and synaptic proteins. *Curr Opin Neurobiol* 2017;45:1–8. [PubMed: 28219682]
19. Oliver KL, Lukic V, Freytag S, Scheffer IE, Berkovic SF, Bahlo M. In silico prioritization based on coexpression can aid epileptic encephalopathy gene discovery. *Neurol Genet* 2016;2:e51. [PubMed: 27066588]
20. Samocha KE, Robinson EB, Sanders SJ, et al. A framework for the interpretation of de novo mutation in human disease. *Nat Genet* 2014;46:944–950. [PubMed: 25086666]
21. Nuytens K, Gantois I, Stijnen P, et al. Haploinsufficiency of the autism candidate gene Neurobeachin induces autism-like behaviors and affects cellular and molecular processes of synaptic plasticity in mice. *Neurobiol Dis* 2013;51:144–151. [PubMed: 23153818]

22. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. *Am J Hum Genet* 2017;100:895–906. [PubMed: 28552198]
23. Guerrini R, Mari F, Dravet C. Idiopathic Myoclonic Epilepsies in Infancy and Early Childhood. *Epileptic syndromes in infancy, childhood and adolescence* 2012.
24. Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. *Arch Neurol* 2011;68:1152–1155. [PubMed: 21555602]
25. Moller RS, Wuttke TV, Helbig I, et al. Mutations in GABRB3: From febrile seizures to epileptic encephalopathies. *Neurology* 2017;88:483–492. [PubMed: 28053010]
26. Sands TT, Choi H. Genetic Testing in Pediatric Epilepsy. *Curr Neurol Neurosci Rep* 2017;17:45. [PubMed: 28405954]
27. Chenier S, Yoon G, Argiropoulos B, et al. CHD2 haploinsufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems. *J Neurodev Disord* 2014;6:9. [PubMed: 24834135]
28. Johannesen KM, Gardella E, Linnankivi T, et al. Defining the phenotypic spectrum of SLC6A1 mutations. *Epilepsia* 2018;59:389–402. [PubMed: 29315614]
29. Carvill GL, McMahon JM, Schneider A, et al. Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. *Am J Hum Genet* 2015;96:808–815. [PubMed: 25865495]
30. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 2014;515:209–215. [PubMed: 25363760]
31. Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 2017;542:433–438. [PubMed: 28135719]
32. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature* 2014;506:179–184. [PubMed: 24463507]
33. Lelieveld SH, Reijnders MR, Pfundt R, et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat Neurosci* 2016;19:1194–1196. [PubMed: 27479843]
34. Iossifov I, O’Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014;515:216–221. [PubMed: 25363768]

Figure 1:**Mutational landscape of *NBEA***

Domain organization of the NBEA protein is based on Uniprot. Boxes indicate functional domains; beach type PH (BPH), BEACH domain, and WD-40 repeat domains (lined) are shown. The positions of variants described in our cohort are shown above the protein and those described in other cohorts are shown below. Black circles represent nonsense, frameshift, and splice site variants, and light circles represent missense variants. All variants identified in a person with a NDD are represented with circle, and the variant identified in a control individual is represented with a triangle.

Table 1:

Summary of clinical and epilepsy characteristics by variant type

Clinical Characteristic	All variants, n = 24	LoF variants*, n = 20	Missense variants, n = 4
Neurodevelopmental disability	24 (100 %)	19 (100 %)	4 (100 %)
Developmental regression	2 (8.33 %)	2 (10 %)	0
Autistic features or Autism	12 (50 %)	10 (50 %)	2 (50 %)
Microcephaly or borderline microcephaly	3 (12.50 %)	3 (15 %)	0
Epilepsy	15 (62.50 %)	12 (60 %)	3 (75 %)
Epilepsy Characteristic	All variants, n = 15	LoF variants, n = 12	Missense variants, n = 3
Age of epilepsy onset			
< 1 year	2 (13.33 %)	2 (16.67 %)	0
1-4 years	11 (73.33 %)	8 (66.67 %)	3 (100 %)
> 4 years	2 (13.33 %)	2 (16.67 %)	0
Generalized seizures	12 (80 %)	10 (83.33 %)	2 (66.67 %)
Myoclonic	7 (46.67 %)	6 (50 %)	1 (33.33 %)
Atonic and/or myoclonic-atonic	5 (33.33 %)	5 (41.67 %)	0
Absence or atypical absence	5 (33.33 %)	5 (41.67 %)	0
Tonic, clonic and/or tonic-clonic	10 (66.67 %)	8 (66.67 %)	2 (66.67 %)
Focal and generalized seizures	4 (26.67 %)	2 (16.67 %)	2 (66.67 %)
Focal seizures only	1 (6.67 %)	0	1 (33.33 %)
Unclassified seizures only	2 (13.33 %)	2 (16.67 %)	0
Epileptiform abnormalities on EEG			
Generalized spike/polyspike and wave	9 (60 %)	8 (66.67 %)	1 (33.33 %)
Focal and generalized discharges	1 (6.67 %)	1 (8.33 %)	0
Focal discharges	2 (13.33 %)	1 (8.33 %)	1 (33.33 %)
Unclassified discharges	2 (13.33 %)	2 (16.67 %)	0
No epileptiform abnormalities	1 (6.67 %)	0	1 (33.33 %)

* All deletions, frameshift, nonsense and splice-site were considered loss of function (LoF) for this table

Table 2:Genotype and phenotype details for individuals with *NBEA* variants

	Variant (NM_015678.4); variant type	Sex, Age (years)	Development	Autism	Seizure Types	Age at 1 st seizure
1	c.1006C>T; p.Arg336*; NS	M, 6	No motor delay; mild speech delay	–	Myoclonic, Astatic, Absence, Myoclonic-Clonic-Tonic, GTC, Tonic, Focal unaware, SE	3 yr
2	c.6829C>T; p.Arg2277*; NS	F, 21	W=18 m.; NV	++	Tonic, GTC	3 yr
3	c.3994C>T; p.Pro1332Ser; MS	M, 4	W=30 m.; speaks some two word phrases	+	None	N/A
4	c.4484del; p.Asn1495Ilefs*17; FS	M, 19	W=2.5 yr; speaks words at 16 yr	++	unknown	3.5-4 yr
5	c.6313G>T; p.Glu2105*; NS	M, 18	W=15-17 m; slightly delayed speech; regression at 2 yr.	–	Myoclonic, Atonic, Atypical Absence, Clonic, GTC	2 yr
6	c.7294_7295dup; p.Glu2433Argfs*3; FS	F, 13	W=prior to 15 mo.; first word=prior to 2 yr.	–	none	N/A
7	c.7707+2T>C; SS	F, 18	W-unavailable, speech delay	–	Febrile, Absence	<1 yr
8	c.6868C>T; p.Gln2290*; NS	M, 3	W=19 m; speaks <10 words at 3 yr	+	none	N/A
9	c.7462G>T; p.Glu2488*; NS	F, 19	W=12 m; speech delay	–	none	N/A
10	c.7230del; p.Asp2411Ilefs*21; FS	M, 9	W=11 m; first word=16 m.	++	Myoclonic, Myoclonic-atic, Atypical Absence, GTC	19 m
11	c.3183delA; p.Glu1062Argfs*8; FS	M, 19	Non-ambulatory; NV	+	Myoclonic, Myoclonic-atic, GTC, Focal unaware, SE	19 m
12	c.1448C>T; p.Ala483Val; MS	F, 11	W=15 m; first word=30 m	–	Febrile, hemi-convulsive, GTC	1 yr
13	c.6637C>T; p.Arg2213*; NS	F, 23	normal until regression at 26 m.	–	Atonic, Tonic, GTC	26 m
14	c.2836C>T; p.His946Tyr; MS	F, 20	W=18 m; words only (no phrases) at 2 yr	–	Nocturnal frontal lobe seizures	2 yr
15	c.3832C>T; p.Arg1278*; NS	F, 5	W=1 yr.; severe speech delay	–	None	N/A
16	c.3362del; p.Asn1121Metfs*9; FS	F, 24	W=2 yr; first word=2 yr	++	Generalized	19 yr
17	c.8401G>A; p.Glu2801Lys; MS	M, 11	W=15 m; 10 words at 24 m	+	Myoclonic, Tonic, Focal, Focal to GTC, Febrile	14 m
18	c.4715C>A; p.Ser1572*; NS	F, 3	W=14 m; 10-15 words at 2 yr	+	None (paroxysmal spells not confirmed to be seizures)	N/A
19	chr13:33957317-36828237 ×1; MGD	M, 15	W=3.5 yr; first word=14 m, stagnation until 4 yr	–	Myoclonic, GTC, epileptic spasms/tonic	18 m
20	chr13:35590335-35940429 ×1; IGD	M, 16	W=15 m; first word=3 yr	–	None	N/A
21	chr13:35574513-36163037 ×1; IGD	M, 16	W=2 yr; NV at 11 yr	+	None	N/A
22	chr13:36038249-36141224 ×1; IGD	M, 11	W-unavailable, IQ=–60	+	Myoclonic, GTC, Tonic	8 m
23	chr13:35963197-36125577 ×1; IGD	M, 5	W=18 m; delayed speech	+	Possible Absences	4 yr
24	chr13:35700830-35887000 ×1; IGD	F, 9	W=17 m; first word=18–20 m	–	Non-convulsive SE, generalized	2 yr

NS=nonsense, MS=missense, FS=frameshift, SS=splice site, MGD=multigene deletion, IGD=intragenic deletion, M=male, F=female, W=age at walking, NV=non-verbal, m= month(s), yr=year(s), Autism: + indicates autistic features, ++ indicates autism diagnosis, GTC = generalized tonic clonic, SE = status epilepticus, N/A=not applicable